Search for: [Abstract = "gender, BMI, smoking status, medications, a previous myocardial infarction\/ stroke, lipid profile, creatinine,AlAT, PAI\-1, and a percentage of patients with CRP level≥3.36 mg\/l. RVO patients had higher percentage of arterial hypertension \(by 58%, p = 0.01\) and higher glucose \(by 4%,p = 0.01\), fibrinogen \(by 17%, p = 0.03\) and tPA \(by 59%, p= 0.001\) compared with controls. Platelet count \(by 10%, p= 0.001\) and total homocysteine \(by 14.5%, p = 0.001\) were lower in RVO group compared with controls. RVO patients were characterized by unfavorably altered plasma fibrin clot properties. Thirty per cent lower clot permeability was found in RVO patients compared with the control group \(6.9\[5.9–8.0\] vs 9.8 \[8.5–10.5\] 10\-9 cm2, p <0.0001\). Compared with controls, RVO patients had 11% shorter lag phase\(41.42 ± 4.59 vs 46.42 ± 4.12 s, p <0.0001\) indicating faster fibrin formation, and 19% greater ΔAbmax \(0.86 \[0.80–0.94\] vs 0.72 \[0.66–0.77\], p <0.0001\), indicating thicker fibrin fibers. D\-Dmax indicating thrombotic mass available for fibrinolytic agents was 22% higher in the RVO group \(4.04 \[3.48–4.55\] vs 3.32 \[3.26–3.43\] mg\/l, p <0.0001\) and29% longer t50% \(9.3 \[8.5–10.2\] vs 7.2 \[6.8–7.7\] min, p<0.0001\) compared with controls. Only D\-Drate was similarin both groups \(0.071 \[0.063–0.074\] vs 0.069 \[0.063–0.073\]mg\/l\/min, p = 0.223\). The differences remained statistically significant after ad"]

Number of results: 1